CRISPR THERAPEUTICS AG Payments To Acquire Equity Securities Fv Ni
CRISPR THERAPEUTICS AG (CRSP) reported Payments To Acquire Equity Securities Fv Ni of $13.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2026-08-03
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for the quarter ending 2026-06-30 was $8.73M, a 85.70% increase year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for the quarter ending 2026-03-31 was $4.62M, a 7.70% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for fiscal 2025 was $9.70M, a 58.16% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for fiscal 2024 was $23.18M.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for fiscal 2023 was $0.00.
- CRISPR THERAPEUTICS AG payments to acquire equity securities fv ni for fiscal 2022 was $0.00.
| Period end | Payments To Acquire Equity Securities Fv Ni 3 month | Payments To Acquire Equity Securities Fv Ni 6 month | Payments To Acquire Equity Securities Fv Ni 9 month | Payments To Acquire Equity Securities Fv Ni 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $13.34M 10-Q · filed 2026-08-03 | $13.34M derived: sum of 3 quarters · filed 2026-08-03 | $13.34M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $4.62M 10-Q · filed 2026-05-04 | $4.62M derived: sum of 2 quarters · filed 2026-05-04 | $4.62M derived: sum of 3 quarters · filed 2026-05-04 | $9.31M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $4.70M derived: sum of 3 quarters · filed 2026-08-03 | $9.70M 10-K · filed 2026-02-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.70M derived: sum of 2 quarters · filed 2026-08-03 | $9.70M 10-Q · filed 2025-11-10 | $12.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $9.70M 10-Q · filed 2026-08-03 | $12.50M derived: sum of 3 quarters · filed 2026-08-03 | $20.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $5.00M 10-Q · filed 2026-05-04 | $7.80M derived: sum of 2 quarters · filed 2026-05-04 | $15.30M derived: sum of 3 quarters · filed 2026-05-04 | $20.68M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $10.30M derived: sum of 2 quarters · filed 2026-02-12 | $15.68M derived: sum of 3 quarters · filed 2026-02-12 | $23.18M 10-K · filed 2026-02-12 |
| 2024-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $12.88M derived: sum of 2 quarters · filed 2025-11-10 | $20.39M 10-Q · filed 2025-11-10 | $20.39M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $12.88M 10-Q · filed 2025-08-04 | $12.88M derived: sum of 3 quarters · filed 2026-02-12 | $12.88M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $7.50M 10-Q · filed 2025-05-06 | $7.50M derived: sum of 2 quarters · filed 2026-02-12 | $7.50M derived: sum of 3 quarters · filed 2026-02-12 | $7.50M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 derived: sum of 3 quarters · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |